Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. develops investigational therapies for genetically driven neuromuscular diseases using its FORCE platform, which is designed to deliver payloads to muscle tissue and the central nervous system. Company news centers on clinical programs in Duchenne muscular dystrophy and myotonic dystrophy type 1, including z-rostudirsen, z-basivarsen, the DELIVER, ACHIEVE and HARMONIA studies, and preclinical work in additional neuromuscular diseases.
Recurring updates include clinical data presentations, FDA interactions and designations, financial results, cash-resource commentary, medical-conference abstracts, access-related research, investor conference participation and Nasdaq inducement equity grants.
Dyne Therapeutics (DYN) will present additional one-year clinical data from the Phase 1/2 ACHIEVE trial of zeleciment basivarsen (DYNE-101) for myotonic dystrophy type 1 at the 31st Annual International Congress of the World Muscle Society and the 2026 Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine, both running September 29–early October 2026.
Presentations will include 6- and 12‑month data from a pooled ACHIEVE multiple ascending dose group (N=25–26) spanning three dose regimens, 12‑month data from a propensity‑matched cohort (N=41–46) from the END‑DM1 natural history study, and updated ACHIEVE safety results. Dyne will also share the average baseline video hand opening time in the blinded ACHIEVE registrational expansion cohort (n=71) and continues to expect topline REC data in Q1 2027.
Dyne Therapeutics (DYN) will present preclinical data for four investigational Duchenne muscular dystrophy (DMD) therapies at the 27th Annual Neuromuscular Study Group Scientific Meeting from September 25-27, 2026, in San Antonio, Texas.
The development candidates DYNE-253, DYNE-245, DYNE-244 and DYNE-255 target DMD mutations amenable to exon skipping of exons 53, 45, 44 and 55, respectively, and are advancing into IND-enabling studies. All use Dyne’s FORCE™ platform, also applied in zeleciment rostudirsen (z-rostudirsen, DYNE-251), which is under FDA review for exon 51 DMD. Presented data will include in vitro exon skipping for all four candidates and in vivo pharmacokinetic and pharmacodynamic results for DYNE-253, including exon skipping and dystrophin levels in a Del52 DMD mouse model.
The poster, titled “Delivering for DMD: Leveraging the FORCE platform to deliver exon skipping oligonucleotides for a broad set of DMD patients,” will be presented on Friday, September 25, from 5:00–7:00 p.m. CT and made available on Dyne’s website.
Dyne Therapeutics (DYN)/b) will participate in three healthcare investor conferences in September 2026, each featuring a management fireside chat in New York, NY.Events include the 2026 Cantor Global Healthcare Conference on September 11 at 10:20 a.m. ET, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 9:15 a.m. ET, and the Baird 2026 Global Healthcare Conference on September 15 at 10:50 a.m. ET. Live webcasts and 90-day replays will be available in the Investors & Media section of Dyne’s website.
Dyne Therapeutics (Nasdaq: DYN) granted inducement equity awards to 11 newly hired employees under Nasdaq Listing Rule 5635(c)(4). The awards include non-statutory stock options for up to 161,300 shares of common stock at the August 19, 2026 closing price and restricted stock units (RSUs) for 51,200 shares.
The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the first anniversary of each employee’s start date and the balance vesting in 12 equal quarterly installments, subject to continued service. The RSUs are scheduled to vest in four equal annual installments over four years, also subject to continued service. The grants were made under Dyne’s 2024 Inducement Stock Incentive Plan and award agreements.
Dyne Therapeutics (Nasdaq: DYN) reported second quarter 2026 results and major clinical, regulatory and financing milestones. The FDA accepted Dyne’s BLA for z-rostudirsen in exon 51 DMD with Priority Review and set a PDUFA target action date of January 21, 2027. Dyne initiated the global Phase 3 FORZETTO trial.
Enrollment of 71 participants was completed in the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, with topline data planned in Q1 2027 and a potential BLA submission targeted for Q3 2027. The FDA cleared the IND for DYNE-302 in FSHD, enabling a Phase 1 MAD trial. Dyne expanded its Hercules term loan facility to up to $400 million and completed a $431 million gross equity offering (about $405 million net). Cash, cash equivalents and marketable securities were $898.5 million as of June 30, 2026, and Dyne expects its cash plus offering proceeds to fund operations into Q2 2028. R&D expenses rose to $152.2 million, G&A to $29.5 million, and net loss was $178.6 million, or $1.08 per share.
Dyne Therapeutics (Nasdaq: DYN) received U.S. FDA clearance of its IND application to begin a Phase 1 randomized, placebo-controlled, double-blind, multiple ascending dose trial of DYNE-302 in ambulatory adults with facioscapulohumeral muscular dystrophy (FSHD). DYNE-302, Dyne’s third clinical program, uses the company’s FORCE platform and a TfR1-targeting Fab to deliver an siRNA payload designed to selectively target DUX4 mRNA, aiming to suppress DUX4 expression and its downstream transcriptome.
According to Dyne, preclinical FSHD models showed robust knockdown of the DUX4 transcriptome in skeletal muscle, significant reversal of muscle fiber damage and functional improvement. The Phase 1 trial will primarily assess safety and tolerability, while also evaluating pharmacokinetics and pharmacodynamics, including changes from baseline in muscle DUX4 transcriptome and plasma KHDC1L levels, a DUX4-regulated biomarker. The first cohort will include nine participants dosed intravenously every four weeks, randomized 2:1 to DYNE-302 or placebo, with options for higher dosing, less frequent administration, and a long-term open-label extension. Dyne plans to pursue a traditional U.S. approval pathway for DYNE-302.
Dyne Therapeutics (Nasdaq: DYN) granted inducement equity awards to 12 newly hired employees under Nasdaq Listing Rule 5635(c)(4), pursuant to the company’s 2024 Inducement Stock Incentive Plan. The grants comprise non-statutory stock options for up to an aggregate 358,600 common shares and restricted stock units (RSUs) covering 116,500 shares.
The stock options have a ten-year term and are scheduled to vest over four years: 25% on the first anniversary of each employee’s start date, with the balance vesting in 12 equal quarterly installments, subject to continued service. The RSUs are scheduled to vest in four equal annual installments over four years from each employee’s start date, also subject to continued service.
Dyne Therapeutics (Nasdaq: DYN) closed its previously announced upsized underwritten public offering of 21,045,000 shares of common stock at $20.50 per share. This total includes 2,745,000 shares sold upon the underwriters’ full exercise of their option to purchase additional shares.
According to Dyne Therapeutics, the offering generated gross proceeds of approximately $431.4 million before underwriting discounts, commissions and expenses. All shares were issued and sold by the company under an automatically effective Form S-3 shelf registration, with Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James and Jones managing the deal.
Dyne Therapeutics (Nasdaq:DYN) has priced an upsized underwritten public offering of 18,300,000 shares of common stock at $20.50 per share, for expected gross proceeds of approximately $375.15 million before fees and expenses. All shares are being sold by Dyne.
The offering is expected to close on or about July 23, 2026, subject to customary conditions. Dyne has granted underwriters a 30-day option to purchase up to an additional 2,745,000 shares. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James and Jones are managing the transaction.
Dyne Therapeutics (Nasdaq: DYN) has commenced an underwritten public offering of $300 million of its common stock. The company also plans to grant underwriters a 30‑day option to purchase up to an additional $45 million of common shares.
All shares in the proposed offering will be sold by Dyne. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital and Raymond James are acting as joint book‑running managers, with Jones as lead manager. The transaction is being conducted under an automatically effective Form S‑3 shelf registration filed on March 5, 2024, and remains subject to market and other conditions, with final terms to be disclosed in a forthcoming final prospectus supplement filed with the SEC.